

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Weaver, Donald F. *et al.*

Serial No.: 09/932676

Filed: August 16, 2001

For: *ANTI-EPILEPTOGENIC AGENTS*

Attorney Docket No.: NCI-006DV2

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Group Art Unit: 1624

Examiner: Rao, Deepak R.

RECEIVED  
JAN 26 2004  
TECH CENTER 1600/2900

"Express Mail" mailing label number EV 355388883 US

Date of Deposit 1/15/04

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Signature

Elizabeth A. Hanley, Esq.

Please Print Name of Person Signing

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed October 7, 2003 during the prosecution of PCT/CA02/00363 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form SB/08, and a copy of the Report and each publication cited thereon are enclosed as well.


This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be

construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(d), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was received by the undersigned on October 15, 2003 (not more than three months prior to the filing of this statement) from the Canadian associate that received the references in a communication from a foreign patent office in a counterpart foreign application on October 7, 2003.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
\_\_\_\_\_  
Elizabeth A. Hanley, Esq.  
Registration No. 33,505  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: 1/15/04

GAD/EAH/JGW/kvj  
Enclosures

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/932676
				Filing Date	August 16, 2001
				First Named Inventor	Weaver, Donald F.
				Art Unit	1624
				Examiner Name	Rao, Deepak R.
Sheet	1	of	1	Attorney Docket Number	NCI-006DV2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	D1	WO 98/40055 A2, A3	09-17-1998	QUEEN'S UNIVERSITY AT KINGSTON [CA/CA]		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	D2	Bigge, C.F. <i>et al.</i> "Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and <i>N</i> -methyl-D-aspartate) receptor and anticonvulsant activity." <i>J. Med. Chem.</i> 38:3720-3740 (1995).	
	D3	Ho, B. <i>et al.</i> "Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores." <i>Eur. J. Med. Chem.</i> 36:265-286 (2001)	
	D4	Ling, R. <i>et al.</i> "Synthesis of 4-alkyl-pyrrolidine-3-carboxylic acid stereoisomers." <i>Tetrahedron</i> 57:6579-6588 (2001)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--